8-K: GoodRx Appoints Christopher McGinnis as New CFO and Treasurer

GoodRx Holdings, Inc. has appointed Christopher A. McGinnis as its new Chief Financial Officer and Treasurer, effective February 4, 2025.

Summary

• GoodRx Holdings, Inc. has appointed Christopher A. McGinnis as Chief Financial Officer and Treasurer, effective February 4, 2025.
• Mr. McGinnis succeeds Romin Nabiey, who served as Interim CFO and will continue as Chief Accounting Officer.
• Prior to joining GoodRx, Mr. McGinnis was CEO of Citizens Rx LLC and held executive roles at Lumeris/Essence Healthcare and Express Scripts Holding Company.
• Mr. McGinnis's employment agreement includes an annual base salary of $500,000 and eligibility for an annual cash incentive bonus targeted at 100% of his base salary.
• He will also receive a one-time signing bonus of $250,000 and is entitled to receive restricted stock units and a stock option, each with an aggregate value of $3,500,000 under the company's 2020 Incentive Award Plan.
• The initial RSU Award and Initial Option will vest with respect to 25% of the shares subject to the awards on February 15, 2026, and as to 1/16 of the shares subject to the award on each quarterly anniversary thereafter, subject to Mr. McGinnis continued employment through the applicable vesting date.
• Mr. McGinnis will become a Tier 1 Participant in the Company's Executive Severance Plan and is subject to a non-disparagement provision and a proprietary information and invention assignment agreement.

Sentiment

Score: 7

Explanation: The document is a standard corporate announcement with neutral to slightly positive sentiment due to the appointment of a new executive. The terms of the employment agreement are typical and do not raise any immediate concerns.

Positives

• GoodRx has secured an experienced CFO with a strong background in pharmacy benefits management and healthcare finance.
• The employment agreement includes standard executive compensation and benefits, aligning Mr. McGinnis's interests with the company's performance.
• The 'best pay' provision under Section 280G of the Internal Revenue Code ensures favorable after-tax treatment for Mr. McGinnis regarding parachute payments.

Negatives

• If Mr. McGinnis's employment is terminated before the first anniversary of the Effective Date under certain circumstances, he will be required to repay a pro-rata portion of the $250,000 signing bonus.
• Mr. McGinnis is subject to non-competition and non-solicitation covenants, which could limit his future career options if he leaves GoodRx.

Risks

• The success of Mr. McGinnis in his role depends on his ability to integrate into the GoodRx team and execute the company's financial strategy.
• The vesting of equity awards is contingent upon continued employment, which could create retention risks.
• The clawback provisions in the employment agreement could impact Mr. McGinnis's compensation if the company's financial results are restated or if he engages in misconduct.

Future Outlook

The document does not contain specific forward-looking statements regarding the company's financial performance or strategic direction beyond the appointment of the new CFO.

Management Comments

• Wendy Barnes, Chief Executive Officer and President, signed the report on behalf of GoodRx Holdings, Inc.

Industry Context

The appointment of a seasoned CFO with experience in pharmacy benefits management aligns with GoodRx's focus on providing affordable healthcare solutions and navigating the complex pharmaceutical landscape.

Comparison to Industry Standards

• Executive compensation packages, including base salary, bonus potential, and equity awards, are generally competitive with industry standards for CFOs at publicly traded companies of similar size and scope.
• The specific terms of the employment agreement, such as vesting schedules and severance provisions, are typical for executive-level positions.

Management Changes

Stakeholder Impact

• Shareholders may view the appointment of an experienced CFO as a positive step towards strengthening the company's financial management.
• Employees may experience changes in leadership and reporting structures within the finance department.
• Customers and suppliers are unlikely to be directly impacted by this appointment.

Next Steps

• Mr. McGinnis will assume his responsibilities as CFO and Treasurer, focusing on the company's financial strategy and operations.
• The company will grant the Initial RSU Award and Initial Option to Mr. McGinnis on the first trading day of the first open window that occurs following the Effective Date.
• The Board or a committee thereof will establish individual and/or Company performance goals for Mr. McGinnis to earn his annual cash incentive bonus.

Key Dates